Shares of Gland Pharma hit their 52-week high in afternoon trade on Monday after the company reported a strong set of March quarter earnings.


The stock climbed 14.67% to Rs 2,142.30 on the NSE, placing it among the top gainers of the session. The scrip had touched its 52-week low of Rs 1,452.20 on May 19, 2025.

For Q4FY26, Gland Pharma reported a 96.56% jump in consolidated profit after tax at Rs 366.67 crore, compared with Rs 186.54 crore in the corresponding quarter last year.

Revenue from operations rose 22.3% year-on-year to Rs 1,742.79 crore in the March quarter, against Rs 1,424.90 crore in the year-ago period.

The company said revenue growth was supported by capacity expansion and ramp-up of new products. It added that contract and pricing renegotiations, cost optimization measures, and operating leverage helped improve margins.

EBITDA rose 48% to Rs 513 crore during the quarter, compared with Rs 347.5 crore in Q4FY25. EBITDA margin expanded to 29% from 24% a year ago.

The board also recommended a final dividend of Rs 20 per share for FY26, subject to shareholder approval at the upcoming AGM. The record date has been fixed as August 11.